Pentoxifylline adjunct to risperidone for negative symptoms of stable schizophrenia: a randomized, double-blind, placebo-controlled trial
International Journal of Neuropsychopharmacology · 2024
DOI: 10.1093/ijnp/pyae051 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Neuropsychopharmacology, 2024. Verfasst von Ahmad Shamabadi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Schizophrenia, Pentoxifylline, Risperidone, Antipsychotic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tehran University of Medical Sciences.
Abstract (Originalsprache)
Background
Negative symptoms of schizophrenia represent an unmet therapeutic need for many patients in whom pentoxifylline may be effective in terms of its dopaminergic, anti-inflammatory, and cerebral blood flow–increasing properties. This study aimed to evaluate pentoxifylline as a therapeutic agent for improving negative symptoms of schizophrenia.
Methods
Chronic schizophrenia outpatients experiencing significant negative symptoms were randomly allocated to receive pentoxifylline 400 mg or matched placebo every 12 hours for 8 weeks. All patients were clinically stable as they had received risperidone for at least 2 months, which was continued. The participants were assessed using the Positive and Negative Syndrome Scale (PANSS), Hamilton Depression Rating Scale, Extrapyramidal Symptom Rating Scale, and side effect checklist.
Results
The patients’ baseline characteristics were comparable between the groups. There was a significant time–treatment interaction effect on PANSS negative subscale scores (ηP2=0.075), with the pentoxifylline group showing significantly greater reductions until weeks 4 (Cohen d = 0.512) and 8 (Cohen d = 0.622). Also, this group showed a significantly better response by week 8. Other PANSS scores, Hamilton Depression Rating Scale scores, Extrapyramidal Symptom Rating Scale scores, and side effect frequencies were comparable between the groups. Pentoxifylline showed a nonsignificant higher remission of 37.1% compared with 14.7% in the placebo group.
Conclusions
Pentoxifylline was safely and tolerably beneficial for the primary negative symptoms of chronic schizophrenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Psychiatry, Razi Hospital, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
Förderung
- Tehran University of Medical Sciences
Zitieren
APA
Shamabadi, A., Rafiei-Tabatabaei, E. S., Kazemzadeh, K., Farahmand, K., Fallahpour, B., Khodaei Ardakani, M. R., & Akhondzadeh, S. (2024). Pentoxifylline adjunct to risperidone for negative symptoms of stable schizophrenia: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae051
Vancouver
Shamabadi A, Rafiei-Tabatabaei ES, Kazemzadeh K, Farahmand K, Fallahpour B, Khodaei Ardakani MR, et al. Pentoxifylline adjunct to risperidone for negative symptoms of stable schizophrenia: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology. 2024. doi:10.1093/ijnp/pyae051
BibTeX
@article{Shamabadi2024,
author = {Shamabadi, Ahmad and Rafiei-Tabatabaei, Elham-Sadat and Kazemzadeh, Kimia and Farahmand, Kimia and Fallahpour, Bita and Khodaei Ardakani, Mohammad-Reza and Akhondzadeh, Shahin},
title = {Pentoxifylline adjunct to risperidone for negative symptoms of stable schizophrenia: a randomized, double-blind, placebo-controlled trial},
journal = {International Journal of Neuropsychopharmacology},
year = {2024},
doi = {10.1093/ijnp/pyae051}
}
EUVIMED